Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
| 适应症 | Prostate Carcinoma |
|---|---|
| 分期 | 2期 |
| 申办方 | Wake Forest University Health Sciences |
| 状态 | 提前终止 |
| 受试者人数 | 46 人 |
| 干预（药物） | Laboratory Biomarker Analysis, Propranolol Hydrochloride, Questionnaire Administration, Survey Administration |
| 开始日期 | 2019年1月15日 |
| 完成日期 | 2021年6月15日 |
| 结果公布日 | 2025年2月17日 |
摘要
This randomized pilot clinical trial studies how well propranolol hydrochloride works in treating patients with prostate cancer who are undergoing surgery. When stressed, the body makes a molecule that may prevent tumor cells from dying, and propranolol hydrochloride may affect the signals in cells that cause tumor cells survival and death.
Mean Level of CREB Phosphorylation
| Group I (Propranolol Hydrochloride) | 1.34 ± .33 West blot band intensity,arbitrary units |
|---|---|
| Group II (no Treatment) | 1.43 ± .46 West blot band intensity,arbitrary units |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate — Aragon Pharmaceuticals, Inc.
- Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced P — National Cancer Institute (NCI)
- M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castr — National Cancer Institute (NCI)
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abirate — Janssen Research & Development, LLC
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Ola — National Cancer Institute (NCI)
- A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Pr — Janssen Research & Development, LLC